WHAT IS CLAIMED IS:

1. A modified T cell for allogeneic adoptive cell therapy in a recipient, wherein the modified T cell is characterized in that it comprises a human T cell which has a native T cell receptor that recognizes a non-human antigen, and said human T cell is modified with at least one therapeutic attribute and is used ~~independently of whether the human T cell has a HLA that is a mismatch, partial match, or match to the HLA of the~~in a recipient~~.~~, wherein the HLA of the human T cell is a mismatch to the HLA of the recipient.

2. The ~~new class of therapeutic cells~~modified T cell of claim 1, wherein the therapeutic attribute is the expression of chimeric antigen receptor.

~~3. The new class of therapeutic cells of claim 1, wherein the therapeutic attribute is the expression of a recombinant protein.~~

~~4. The new class of therapeutic cells of claim 3, wherein the recombinant protein is a cytokine.~~

~~5. The new class of therapeutic cells of claim 4, wherein the cytokine is IL2, IL7, or GM-CFS.~~

~~6. The new class of therapeutic cells of claim 1, wherein the therapeutic attribute is the expression of a receptor that recognizes a cytokine.~~

~~7. The new class of therapeutic cells of claim 6, wherein the cytokine is IL4.~~

~~8. The new class of therapeutic cells of any one of claims 1 to 7, wherein said therapeutic cells express a suicide gene.~~

~~9. The new class of therapeutic cells of claim 8, wherein the suicide gene is thymidine kinase from herpes simplex virus 1, or fas associated death domain-containing protein, or caspase 9.~~

~~10~~3. The ~~new class of therapeutic cells~~modified T cell of any one of claims 1 to ~~9~~2, wherein said therapeutic cells have a native antigen receptor that only recognizes a single epitope of the non-human antigen.

~~11~~4. The ~~new class of therapeutic cells~~modified T cell of any one of claims 1 to ~~10~~2, wherein the non-human antigen is from a virus, from a bacteria or from a fungus.

~~12. The new class of therapeutic cells of any one of claims 1 to 11, wherein said cells have a HLA that is a partial match to the HLA of the recipient.~~

~~13. The new class of therapeutic cells of any one of claims 1 to 11, wherein said cells have a HLA that is a mismatch to the HLA of the recipient.~~